WO1999041411A2 - Method for diagnosis and treatment of disorders of carbohydrate metabolism - Google Patents
Method for diagnosis and treatment of disorders of carbohydrate metabolism Download PDFInfo
- Publication number
- WO1999041411A2 WO1999041411A2 PCT/SE1999/000177 SE9900177W WO9941411A2 WO 1999041411 A2 WO1999041411 A2 WO 1999041411A2 SE 9900177 W SE9900177 W SE 9900177W WO 9941411 A2 WO9941411 A2 WO 9941411A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- promoter
- adenylate cyclase
- iii
- gene
- enhanced
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 27
- 230000023852 carbohydrate metabolic process Effects 0.000 title claims abstract description 18
- 235000021256 carbohydrate metabolism Nutrition 0.000 title claims abstract description 18
- 208000035475 disorder Diseases 0.000 title description 21
- 238000003745 diagnosis Methods 0.000 title description 9
- 230000000694 effects Effects 0.000 claims abstract description 99
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract description 80
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract description 77
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 77
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 73
- 241001465754 Metazoa Species 0.000 claims abstract description 43
- 230000014509 gene expression Effects 0.000 claims abstract description 41
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 36
- 101150098499 III gene Proteins 0.000 claims abstract description 22
- 102000004877 Insulin Human genes 0.000 claims abstract description 18
- 108090001061 Insulin Proteins 0.000 claims abstract description 18
- 229940125396 insulin Drugs 0.000 claims abstract description 18
- 230000004044 response Effects 0.000 claims abstract description 12
- 230000009261 transgenic effect Effects 0.000 claims abstract description 8
- 239000005557 antagonist Substances 0.000 claims abstract description 6
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- 239000003112 inhibitor Substances 0.000 claims abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 101
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 71
- 239000008103 glucose Substances 0.000 claims description 71
- 230000001965 increasing effect Effects 0.000 claims description 61
- 108020004999 messenger RNA Proteins 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 52
- 241000700159 Rattus Species 0.000 claims description 49
- 108020004414 DNA Proteins 0.000 claims description 45
- 230000035772 mutation Effects 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 25
- 210000004153 islets of langerhan Anatomy 0.000 claims description 19
- 108060001084 Luciferase Proteins 0.000 claims description 16
- 238000003752 polymerase chain reaction Methods 0.000 claims description 16
- 208000035197 Disorder of carbohydrate metabolism Diseases 0.000 claims description 7
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 108700008625 Reporter Genes Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000000869 mutational effect Effects 0.000 claims 1
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 93
- 239000000523 sample Substances 0.000 description 74
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 47
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 47
- 238000001514 detection method Methods 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 230000003914 insulin secretion Effects 0.000 description 26
- 239000013598 vector Substances 0.000 description 25
- 239000013615 primer Substances 0.000 description 21
- 230000000295 complement effect Effects 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 15
- 230000006362 insulin response pathway Effects 0.000 description 15
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000001890 transfection Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 108700009124 Transcription Initiation Site Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101710095468 Cyclase Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000037429 base substitution Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011778 Cystinuria Diseases 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101000959334 Rattus norvegicus Adenylate cyclase type 3 Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091006208 SLC3 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010023456 adenylate cyclase 3 Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 150000004160 forskolin derivatives Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- -1 promoter Proteins 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- Diabetes mellitus is a serious and chronic disorder that affects 6% of the world's population and all ethnic groups. In the United States, approximately 5% of the population has diabetes. Symptoms of diabetes include hyperglycemia and reduced production or release of insulin. Diabetes mellitus is classified into two types, type I diabetes or insulin-dependent diabetes mellitus (IDDM) and type II diabetes or non-insulin-dependent diabetes mellitus (NIDDM). Type I diabetes, in which the pancreas has stopped producing insulin, affects 10% of all diabetics, often begins in childhood and is known as juvenile onset diabetes.
- IDDM insulin-dependent diabetes mellitus
- NIDDM non-insulin-dependent diabetes mellitus
- Type II diabetes In the more prevalent type II diabetes, affecting 90% of all diabetics, the pancreas can produce insulin, but insulin secretion in response to meals is diminished, and the diabetic's tissues are not as responsive to insulin as tissues from a non-diabetic. Type II diabetes is also known as adult onset diabetes.
- the present invention relates to a method of detecting a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), by analyzing a promoter of an adenylate cyclase III gene having enhanced activity in cells or tissue from a patient.
- the promoter having enhanced activity can be detected either directly by its sequence, or indirectly by the levels of or activities of gene products of the adenylate cyclase III gene. Detection can be accomplished employing, on cells or tissues from the patient, methods such as polymerase chain reaction, expressing a reporter gene under the control of the promoter, determining adenylate cyclase III mRNA levels, measuring the amount or activity of adenylate cyclase III., or determining cAMP levels.
- the present invention also relates to a promoter having enhanced activity from an adenylate cyclase LU gene, and isolated DNA molecules containing this promoter.
- the promoter having enhanced activity is a naturally occurring promoter that is stronger titan the corresponding wild type promoter.
- an enhanced promoter is found in the adenylate cyclase III gene from an animal with type II diabetes, preferably a diabetic GK rat.
- the enhanced promoter can be part of a transgenic animal,
- the invention in another embodiment, relates to a method of treating a patient having a disorder in carbohydrate metabolism, such as type II diabetes (NIDDM), and a method of enhancing or restoring a patient's response to insulin.
- a disorder in carbohydrate metabolism such as type II diabetes (NIDDM)
- NIDDM type II diabetes
- Each of these methods includes administering to the patient a down regulator, an antagonist, or an inhibitor of expression of the adenylate cyclase III gene, or of the activity of one of its gene products,
- Figure 3 illustrates AC-III mRNA expression determined by in situ hybridization in single islets in the presence of 3.3 mM glucose (A: control, B: diabetic); 3.3 mM glucose and 5 ⁇ M forskolin (C: control, D: diabetic); 16.7 mM glucose (E: control, F: diabetic); 16.7 mM glucose and 5 ⁇ M forskolin (G: control; H: diabetic).
- Figure 4 illustrates a schematic structure of the promoter region of AC-III gene, Exons are represented by a solid box and the transcription start site is marked by a curved arrow. Two point-mutations upstream from the transcription start site were observed at positions -28 (A ⁇ G) and -358 (A ⁇ C) only in islets and peripheral blood cells from diabetic animals.
- Figure 5 illustrates transfection analysis of the two mutations in the promoter region of AC-III gene in the diabetic rat.
- AC-III refers to adenylate cyclase III (adenylyl cyclase III or adenyl cyclase III), which is an isozyme of adenylate cyclase, including the isozyme whose expression is enhanced in islet cells of GK strain diabetic rats.
- AC-III is used to refer to the related gene, promoter, mRNA, and the like and the full expression adenylate cyclase III is used to refer to the adenylate cyclase III protein.
- a promoter of the adenylate cyclase III gene (AC-III promoter) having enhanced activity, or an enhanced promoter is a promoter of the AC-III gene that is a more powerful promoter than a wild-type AC-III promoter.
- a more powerful promoter has effects such as increasing expression of a gene, increasing the amount of mRNA transcript, and the like, compared to the wild-type promoter.
- wild type refers to a dominant genotype which naturally occurs in the normal population (i.e., members of the population not afflicted with type II diabetes (NIDDM) or a like disorder of glucose metabolism).
- a wild type AC-HI promoter is a promoter that is functionally coupled to the wild type AC-III gene
- a preferred promoter of the adenylate cyclase III gene having enhanced activity has the sequence of the wild-type AC-III promoter with one or more base substitutions, additions, or deletions. That is, a preferred promoter of the adenylate cyclase III gene having enhanced activity is a mutant of a wild type AC-III promoter.
- an individual is "at risk” for developing type II diabetes (NIDDM), or another disorder of carbohydrate metabolism, when the individual has traits or characteristics, such as an enhanced AC-III promoter, that correlate with later development of type II diabetes (NIDDM), or the disorder of carbohydrate metabolism.
- disorder of carbohydrate metabolism refers to disorders such as non-insulin dependent diabetes mellitus (NIDDM) or type II diabetes, preclinical stages of these disorders, other disorders affecting the insulin response, and syndromes and side effects related to these disorders.
- NIDDM non-insulin dependent diabetes mellitus
- type II diabetes preclinical stages of these disorders, other disorders affecting the insulin response, and syndromes and side effects related to these disorders.
- diabetes refers to either NIDDM, IDDM, or both.
- the present invention relates to a promoter of the adenylate cyclase 111 gene having enhanced activity and its correlation with and role in disorders of carbohydrate metabolism, such as type II diabetes (NIDDM).
- NIDDM type II diabetes
- Spontaneously diabetic animals show decreased insulin release in response to glucose, exhibit elevated cAMP at high glucose concentrations, and overexpress the AC-III gene.
- the present invention results from the discovery that such spontaneously diabetic animals have a promoter of the AC-III gene that has enhanced activity compared to the wild type AC-III promoter.
- the AC-III promoter having enhanced activity is a causative agent of the observed overexpression of the AC-III gene and is involved in the observed decreased insulin release in response to glucose and elevated cAMP at high glucose concentrations, Increased levels of AC-III promoter activity, of AC-III expression, and of cAMP are each part of a reduced response of islet cells to glucose levels and an impaired insulin response to glucose.
- Detecting or modulating the enhanced AC- III promoter, or its downstream effects provides for methods and compositions for diagnosing and treating disorders of carbohydrate metabolism characterized by an impaired insulin response, such as type II diabetes (NIDDM).
- Methods and compositions for diagnosing and treating disorders of glucose metabolism can employ various manifestations of the AC-III promoter having enhanced activity.
- this enhanced AC-III promoter provides a genetic marker for the risk or presence of disorders of glucose metabolism.
- Downstream products, such as AC-III mRNA, AC-III protein, and cAMP also provide distinctive, detectable features indicating the presence of the AC-III promoter having enhanced activity.
- the enhanced AC-III promoter increases expression of the AC-III gene, which results in increased AC-III mRNA levels and increased AC-III protein, which in turn increases c MP levels.
- enhanced activity of the AC-III promoter is associated with the insulin response. The insulin response can be measured in a subject's cells or tissues for diagnostic purposes.
- the type II diabetes (NIDDM) associated AC-III promoter having enhanced activity provides avenues for diagnosis of type II diabetes (NIDDM) and other disorders of carbohydrate metabolism.
- the AC-III promoter is found in genetic material of cells and tissues throughout an animal regardless of whetlier they express AC-ffi.
- various cells and tissues such as blood or pancreatic tissue, can serve as a source of DNA or other biological materials for detecting the AC-III promoter itself. Detection of the enhanced AC-III promoter in a patient indicates that the patient is at risk to develop type II diabetes (NIDDM), if no other symptoms are already apparent.
- detection of the enhanced AC-III promoter can confirm an otherwise uncertain diagnosis.
- detection of the enhanced AC- III promoter can indicate type II diabetes (NIDDM).
- the presence of the enhanced AC-III promoter can be detected either directly, by determining the sequence of the patient's AC-HI gene promoter regions, or indirectly. Indirect detection of the enhanced AC-III promoter includes detecting the effect of this promoter on effector binding to the AC-III gene or associated regulatory sequences, on the structure of the AC-III gene, on expression of the AC- III gene, or the like.
- the enhanced AC-III promoter can also be detected by its production higher levels of an indicator protein in heterologous expression systems, compared to a wild-type AC-III promoter.
- Table 1 The sequence surrounding the start site of a wild type adenylate cyclase III gene. The transcription start site is underlined.
- the AC-III gene from pancreatic ⁇ -islet cells of a spontaneously diabetic animal has been sequenced (Table 2, SEQ ID NO. 2) and includes a wild type coding sequence and base substitutions in an untranslated promoter region.
- An enhanced promoter of the AC-III gene in GK diabetic rats has two point mutations compared to the same promoter in control rats.
- the enhanced AC-III promoter has an A to C point mutation at position -358 and A to G at position -28. (Table 2, SEQ. ID NO. 2)
- Table 2 The sequence surrounding the start site of the adenylate cyclase gene from GK diabetic rats including an enhanced promoter of the adenylate cyclase III gene.
- the transcription start site is underlined.
- the residues that differ from the wild type sequence are in bold.
- a method for detecting an AC-III promoter having enhanced activity compares the sequence or a signal representing the sequence, of an experimental sample containing an AC-III promoter with a one or more control samples containing either a known wild-type or a known enhanced AC-III promoter.
- An experimental sample that contains a sequence or produces a signal that matches a known enhanced AC-III promoter contains an AC-HI promoter with enhanced activity.
- An experimental sample that contains a sequence or produces a signal that matches a known wild-type AC-III promoter contains a wild-type AC-III promoter.
- An experimental sample that contains a sequence or produces a signal different from a known enhanced AC-III promoter or wild type AC-III promoter may be an AC-III promoter with enhanced activity, but any enhanced activity of the experimental promoter must be measured.
- an enhanced AC-III promoter Many diagnostic methods for detection and analysis of a sequence of a nucleic acid, such as an enhanced AC-III promoter, are known to those of skill in the art. These include, for example, direct sequencing, ARMS (amplification refractory mutation system), restriction endonuclease assays, oligonucleotide hybridization techniques, and immunoassays. These methods can be employed for detecting an enhanced AC-III gene in a variety of cells or tissues, such as blood or pancreatic tissue. While some commonly used procedures are described below, other available methods are included in the scope of the invention.
- DNA obtained from a blood or tissue sample from a patient in need of diagnosis for type II diabetes (NIDDM) or another disorder of carbohydrate metabolism can be sequenced by known methods and compared to the wild type sequence to indicate an enhanced AC-III promoter.
- DNA is obtained from blood or tissue of a patient suspected of being at risk for, or having, type II diabetes (NIDDM) or another disorder of carbohydrate metabolism and then separated by gel electrophoresis. Following electrophoresis, the double stranded DNA is converted to single stranded DNA, for example, by soaking the gel in NaOH, The DNA is then transferred to a sheet of nitrocellulose, The transferred DNA is contacted with a labeled probe.
- labeled probe can be applied to the nitrocellulose after it dries.
- a "probe” is a nucleic acid sequence that is complementary to the sequence of interest.
- the probe can be either a DNA sequence or an RNA sequence.
- Preferably the probe is about 8 to 16 nucleotides in length.
- a radioactive label, such as 32 P is an example of a suitable label.
- Other suitable labels include fluorophores or an enzyme which catalyzes a color producing reaction (e.g., horse radish peroxidase).
- hybridize means that the probe will form a double-stranded molecule with the specific DNA sequence by complementary base pairing under conditions of high stringency (e.g., 65 °C; 0.1 x SSC; Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, New York: Cold Spring Harbor Press (1989)). After the probe is allowed to hybridize to the DNA, excess probe is washed away. The hybridized DNA is easily visualized from the labeled probe using known techniques. Hybridization of the probe indicates that the sample DNA contains a sequence that is complementary to the labeled probe.
- probes can be used for detecting an AC-III promoter having enhanced activity.
- a probe complementary to a sequence in an enhanced promoter, but not in a wild-type promoter will hybridize to and result in a signal from an experimental sample that has the sequence of the enhanced promoter, but not an experimental sample having the wild-type sequence. This signal indicates detection of an enhanced promoter in the experimental sample.
- a probe complementary to a sequence in a wild-type promoter, but not in an enhanced promoter will hybridize to and result in a signal from an experimental sample that has the sequence of the wild- type promoter, but not an experimental sample having the enhanced promoter sequence. In this case a signal indicates detection of a wild type promoter in the experimental sample.
- One of skill in the art realizes that other combinations of probes and signals are possible for indicating the presence of an enhanced promoter.
- PCR Polymerase chain reaction
- An exemplary method includes developing oligonucleotide primers that hybridize to opposite strands of DNA flanking the enhanced AC-III promoter.
- a "primer" is a short nucleotide sequence which is complementary to a DNA sequence flanlcing the DNA sequence of interest and that serves to prime chain elongation by a suitable polymerase.
- the primer is about 15 to 20 nucleotides in length.
- the specific fragment defined by the primers exponentially accumulates by repeated cycles of denaturation, oligonucleotide primer annealing and primer extension.
- the amplified domain can then be analyzed by hybridization or screening techniques, such as the Southern blot technique described above. Suitable oligonucleotide primers are shown in Example 5.
- ARMS amplification refractory mutation system
- amplification refractory mutation system is a PCR based technique in which an oligonucleotide primer that is complementary to either a wild-type allele or mutant allele is used to amplify a DNA sample.
- a description of ARMS can be found in Current Protocols in Human Genetics, Chapter 9.8, John Wiley & Sons, ed by Dracopoli et al. (1995).
- a pair of primers is used in which one primer is complementary to a known mutant sequence. If the DNA sample is amplified, the preseuce of the mutant sequence is confirmed. Lack of amplification indicates that the mutant sequence is not present. For detecting an AC-III promoter having enhanced activity, the mutant sequence is the sequence of the enhanced promoter.
- the primers are complementary to wild-type sequences. Amplification of the DNA sample, indicates that the DNA has the wild type sequence complementary to the primers, If no amplification occurs, the DNA likely contains a mutation at the sequence where hybridization should have occurred and may contain an enhanced promoter, but any enhanced activity of the experimental promoter must be measured.
- Restriction endonuclease assays can also be used to screen a sample of DNA from a suitable cell or tissue, such as blood or pancreatic tissue, for mutants. Such assays are described and used by Pras et al., "Mutations in the SLC3 Al transporter gene hi Cystinuria " Am. J. Hum. Genet., 56:1297-1303 (1995). Briefly, a DNA sample is amplified and then exposed to restriction endonucleases that will or will not cleave the DNA depending on whether or not a mutation is present. After cleavage, the size of restriction fragments are observed to determine whether or not cleavage occurred. The pattern of cleavage represents structural differences.
- restriction endonucleases are selected to provide different cleavage for the wild-type AC-III promoter and the enhanced AC-III promoter.
- Cleavage of an experimental sample of DNA yields a restriction pattern that is compared to the restriction patterns for the control wild-type and enhanced AC-III promoters.
- a match of one of the control patterns by the experimental pattern identifies the experimental sequence as matching that control sequence. If the experimental pattern does not match either of the control patterns, the DNA likely contains a mutation at the promoter sequence and may contain an enhanced promoter, but any enhanced activity of the experimental promoter must be measured.
- Hybridization techniques such as dot blots, are known to one of skill in the art and can be used to determine whetlier a DNA sample contains a specific sequence, such as the sequence of an AC-HI promoter having enhanced activity.
- a specific sequence such as the sequence of an AC-HI promoter having enhanced activity.
- a DNA sample is denatured and exposed to a labeled probe which is complementary to the sequence of a wild-type AC-HI promoter or to an enhanced AC-HI promoter.
- Hybridization of a probe that is complementary to the wild-type AC-IH promoter indicates that the wild-type AC-III promoter is present. If the wild type probe does not hybridize to the DNA in the sample, the wild-type AC-III promoter is not present.
- a probe that is complementary to an enhanced AC-IH promoter can be used.
- Hybridization of a probe that is complementary to the enhanced AC-IH promoter indicates that the enhanced AC- ⁇ i promoter is present. If the enhanced probe does not hybridize to the DNA in the sample, the enhanced AC- ⁇ i promoter is not present, If no hybridization occurs with either a wild-type or an enhance probe, the DNA likely contains a mutation at the sequence where hybridization should have occurred and may contain an enhanced promoter, but any enhanced activity of the experimental promoter must be measured.
- the enhanced AC-III promoter can also be detected by its production of higher levels of an indicator protein in heterologous expression systems, compared to a wild-type AC -HI promoter.
- Increased heterologous expression can be detected in several ways known to those of skill in the art.
- Increased heterologous expression using the AC-III promoter from a patient can be detected either directly, by measuring the presence of the transcript from heterologous expression, or indirectly.
- Indirect detection of increased heterologous expression using the AC-III promoter from a patient includes detecting the activity of or the presence of an indicator such as a reporter protein, typically an enzyme such as luciferase or ⁇ -galactosidase, or the like.
- an experimental sample of DNA can be extracted from a suitable tissue, such as blood or pancreatic tissue, and tested for the presence of an AC - ⁇ i promoter have enhanced activity.
- the experimental sample of DNA is inserted into an expression vector adjacent to, or in a position from which it can control the expression of, a heterologous gene.
- the heterologous gene encodes a detectable marker such as a detectable polynucleotide or protein.
- the heterologous gene encodes an enzyme that catalyzes a light or color producing reaction, such as luciferase or ⁇ -galactosidase, whose signal represents the level of gene expression.
- the level of expression of the heterologous gene is compared to control levels of expression produced by a wild type AC-III promoter or an enhanced AC-III promoter.
- An enhance promoter produces greater expression of the heterologous gene than a wild type promoter.
- Enhanced AC-III promoter activity results in enhanced AC-IH gene expression and production of increased amounts of an AC-III mRNA transcript encoding an active adenylate cyclase III.
- the enhanced AC-III promoter does not alter the sequence of the mRNA compared to the wild-type AC-III promoter.
- the level of expression of the AC-III mRNA transcript is increased in islet cells from a diabetic animal compared to a control animal at high and low glucose levels. Such an effect can also be produced in an in vitro system.
- the enhanced AC-IH promoter produces increased levels of AC- ⁇ i mRNA transcript both in vivo and in vitro, and either type of system can be used in methods to detect an AC-III promoter having enhanced activity.
- Increased expression of AC-III mRNA correlates with the presence of the enhanced AC-III promoter and is characteristic of disorders of carbohydrate metabolism such as type II diabetes (NIDDM).
- Detection of increased levels of AC-III mRNA transcript in a patient indicates that the patient is at risk to develop type II diabetes (NIDDM), if no other symptoms are already apparent, hi the presence of early stage, but inconclusive, symptoms of type ⁇ diabetes (NIDDM), detection of increased levels of AC-III mRNA transcript can confirm an otherwise uncertain diagnosis. In a diabetic patient, detection of increased levels of AC-III mRNA transcript can indicate type II diabetes (NIDDM). Increased levels mRNA transcript can be detected in several ways known to those of skill in the art. Increased levels of AC-III mRNA transcript can be detected either directly, by measuring the presence of the mRNA, or indirectly.
- increased levels of AC-III mRNA result in increased production of AC-III protein and adenylate cyclase activity, in both in vitro and in vivo systems.
- Increased levels of AC-III protein can be determined by increased levels of cAMP, in both in vitro and in vivo systems.
- Increased levels of cAMP produce biological effects, such as changes in insulin levels.
- Indirect detection of increased levels of AC-HI mRNA transcript includes detecting insulin levels, AC-UI protein, adenylate cyclase activity, cAMP levels, or the like. Each of these indirect indicators of AC ⁇ I mRNA level can be detected by common methods known in the art. Some methods for detecting AC-III protein or activity levels are described hereinbelow, additional methods are known to those of skill in the art.
- nucleic acid such as an AC-III mRNA
- diagnostic methods for detection and analysis of a sequence of a nucleic acid include, for example, direct certain of the methods described hereinabove for detecting a DNA sequence or downstream products of a DNA sequence. These methods include either directly, or after reverse transcription of the mRNA to DNA, as appropriate or desired, restriction endonuclease assays, oligonucleotide hybridization techniques, and immunoassays. While some commonly used procedures are described below, other available methods are included in the scope of the invention.
- the presence or amount of an mRNA transcript can be determined by Northern Blot Techniques, following a procedure similar to that outlined for the Southern Blot Technique,
- adenylate cyclase III protein expression When mRNA production is coupled to protein production, the levels of AC- III mRNA production is reflected in adenylate cyclase III protein expression, which can be detected by imrnunoassay, for example by Western Blot Techniques.
- imrnunoassay for example by Western Blot Techniques.
- a tissue sample is obtained from an individual and separated by gel electrophoresis. Following electrophoresis, the proteins are transferred to nitrocelhdose. The proteins are then contacted with a labeled probe, for example, by applying the labeled probe to the nitrocellulose after it is dried.
- Suitable probes include l beled anti-adenylate cyclase III antibodies, preferably those antibodies specific for a specific epitope.
- Exemplary labels include radioactive isotopes, enzymes, fluorophores and chromophores. After excess antibody is rinsed away, the presence of the specific protein/antibody complex is easily determined by known methods, for example by development of the label attached to the anti-adenylate cyclase IH antibody, or by the use of secondary antibodies.
- Cells such as islet cells, from a diabetic animal having the enhanced AC-HI promoter produce increased levels of adenylate cyclase HI under conditions of high glucose, compared to control cells.
- Increased levels of adenylate cyclase ⁇ i can be detected either directly, by measuring the presence of adenylate cyclase III by, for example, imrnunoassay, or indirectly. Indirect detection of increased levels of adenylate cyclase III include detecting its activity in a direct or coupled enzyme assay, or the like.
- Increased levels of adenylate cyclase III can be detected in several ways known to those of skill in the art.
- Detection of increased levels of adenylate cyclase HI in cells from a patient indicates that the patient is at risk to develop type H diabetes (NIDDM), if no other symptoms are already apparent.
- type H diabetes NIDDM
- detection of increased levels of adenylate cyclase III in cells from a patient can confirm an otherwise uncertain diagnosis.
- detection of increased levels of adenylate cyclase III in cells from a patient can indicate the type of type II diabetes (NIDDM).
- the levels of adenylate cyclase III protein expression can be detected by imrnunoassay, for example by Western Blot Techniques.
- imrnunoassay for example by Western Blot Techniques.
- a tissue sample is obtained from an individual and separated by gel electrophoresis, Following electrophoresis, the proteins are transferred to nitrocellulose.
- the proteins are then contacted with a labeled probe, for example, by applying the labeled probe to the nitrocellulose after it is dried.
- Suitable probes include labeled anti-adenylate cyclase III antibodies, preferably those antibodies specific for a specific epitope.
- Exemplary labels include radioactive isotopes, enzymes, fluorophores and chromophores. After excess antibody is rinsed away, the presence of the specific protein/antibody complex is easily determined by known methods, for example by development of the label attached to the anti-adenylate cyclase III antibody, or by the use of secondary antibodies.
- Adenylate cyclase activity assays are well described in the scientific literature. For example, suitable assays are described by Kuo et al. "Adenylate cyclase in islets of Langerhans. Isolation of islets and regulation of adenylate cyclase activity by various hormones and agents.” J. Biol. Che . 248:2705-2711 (1972).
- Cells, such as islet cells, from a diabetic animal having the enhanced AC-III promoter produce increased levels of cAMP under conditions of high glucose, compared to control cells.
- Increased levels of c AMP can be detected in several ways known to those of skill in the art. Increased levels of cAMP can be detected either directly, by measuring the presence of c AMP by, for example, chromatography or radioimmunoassay, or indirectly. Indirect detection of increased levels of cAMP includes using cAMP as a substrate for an indicator enzyme or as a ligand for an indicator protein, or the like. Detection of increased levels of cAMP in cells from a patient indicates that the patient is at risk to develop type II diabetes (NIDDM), if no other symptoms are already apparent.
- NIDDM type II diabetes
- NIDDM type II diabetes
- detection of increased levels of cAMP in cells from a patient can confirm an otherwise uncertain diagnosis.
- detection of increased levels of cAMP in cells from a patient can indicate the type of type II diabetes (NIDDM).
- cAMP levels in islet cells from a diabetic animal with the enhanced AC-III promoter are similar or increased compared to control cells.
- the amounts of AC-IH mRNA and cAMP are much higher in islet cells from a diabetic animal than in control cells.
- Increased levels of adenylate cyclase and cAMP at high glucose concentrations correlate with the presence of the enhanced AC-III promoter and are characteristic of disorders of carbohydrate metabolism such as type II diabetes (NIDDM).
- Cells such as islet cells, from a diabetic animal having the enhanced the AC- III promoter produce decreased levels of insulin secretion under conditions of high glucose, compared to control cells.
- Decreased levels of insulin secretion can be detected in several ways known to those of skill in the art. Decreased levels of insulin can be detected either directly, by measuring the presence of insulin by, for example, chromatography or radioimmunoassay, or indirectly. Detection of decreased levels of insulin secretion from cells of a patient indicates that the patient is at risk to develop type II diabetes (NIDDM), if no other symptoms are already apparent.
- NIDDM type II diabetes
- the type II diabetes (NIDDM) associated enhanced AC-III promoter provides avenues for treatment or therapy of type II diabetes (NIDDM).
- the presence of the enhanced AC-III promoter correlates with diminished insulin response to glucose in islet cells from diabetic animals.
- Antagonizing the effects of the enhanced AC- ⁇ i promoter can restore a normal insulin response.
- the effects of the enhanced AC-III promoter can be antagonized in any way known to those of skill in the art for down regulating gene expression or for antagonizing or inhibiting the function or activity of a gene product, such as an mRNA or a protein.
- gene therapy can be used to remove or replace the enhanced AC- ⁇ i promoter or the AC-HI gene.
- Direct methods for antagonizing the enhanced AC-III promoter include inhibiting its enhanced activity by binding of a sense or antisense targeted binding molecule, by binding of a protein or small molecule antagonist, by preventing binding of activators (or other cofactors) necessary for activity of the enhanced AC- III promoter, or the like.
- Downstream targets include the mRNA transcript, adenylate cyclase-III (the protein and its activity), and cAMP.
- a variety of methods can be used antagonize or inhibit the effect of increased levels of AC ⁇ I mRNA.
- the function of the mRNA can be disrupted by inducing its degradation, by preventing its export from the nucleus, by binding of a sense or antisense targeted binding molecule, by binding of a protein or small molecule antagonist, by preventing binding of the ribosome or cofactors in translation, or the like.
- a variety of methods can be used antagonize or inhibit the effect of increased levels of adenylate cyclase III.
- the function of the adenylate cyclase III can be disrupted by preventing its synthesis, by inducing its degradation, by preventing its folding, by inhibiting its activity, or the like.
- a variety of methods can be used antagonize or inhibit the effect of increased levels of cAMP.
- the effects of increased levels of cAMP can be disrupted by antagonizing or inhibiting the downstream receptors or enzymes that interact with cAMP, by inhibiting cAMP synthesis, by inducing cAMP degradation, or the like.
- the enhanced AC-III promoter provided in this application useful for the development of transgenic animals having disorders in carbohydrate metabolism, such as type ⁇ diabetes (NIDDM). Such transgenic animals are used, for example, to screen compounds for treating such disorders.
- Useful variations of a transgenic animal include "knock in” animals. In a “knock in” animal, the wild type AC-III promoter is deleted and replaced by the enhanced AC-III promoter. Experiments can be performed on the animal to determine the effects of this transition, and to test compounds that down regulate, inhibit or antagonize the enhance promoter or associated gene products.
- islets were surgically removed from the rats and isolated as described in Korsgren et al. "Effects of hyperglycaemia on function of isolated mouse pancreatic islets transplanted under the kidney capsule.” Diabetes 38:510- 515 (1989). Briefly, islets were isolated from pancreas of both control and GK rats by digestion with collagenase (Boehringer-Mannheim, Mannheim, Germany). The islets were cultured for 48 hours in RPMI-1640 supplemented with 11 mM glucose and 10% (vol/vol) fetal calf serum.
- KRB Krebs-Ringer bicarbonate
- bovine plasma albumin Sigma Chemical Co., St. Louis, MO, USA
- Insulin secretion, cAMP generation, and light intensity from transfection studies are expressed as the mean + SEM. All statistical tests were performed with SigmaStat for Windows Version 1.0 (Jandel Scientific Software, Ekrath, Germany). Test of significance of differences were performed using the r-test for unpaired data and the Mann- Whitney Rank Sum test.
- Insulin release from islets of diabetic animals was measured, and compared to levels from control islets, to correlate the insulin levels with indicators such as cAMP levels and adenylate cyclase expression levels.
- Forskolin strongly stimulates adenylyl cyclase (AC) and cAMP generation and is used as another control for effects on AC activity. Forskolin is used to determine whether the observed effect on insulin release is due to increased sensitivity of the cells to cAMP, or increased levels of cAMP.
- AC adenylyl cyclase
- Insulin release was determined in batches of 20 islets incubated for 45 minutes at 37 °C in 1000 ⁇ l KRB supplemented with 3.3 mM or 16.7 mM glucose alone and with 5 ⁇ M forskolin (Sigma) at both glucose concentrations. After the incubation period, 900 ⁇ l of the effluent was removed and frozen at -20 °C for subsequent analysis by radioimmunoassay (RIA) of insulin (Herbert, et al., 1965).
- RIA radioimmunoassay
- insulin release was decreased in diabetic islets at 3.3 mM glucose (p ⁇ 0.002) and at 16.7 mM glucose (p ⁇ .0001).
- stimulation by forskolin increased insulin release approximately 4-fold at both 3.3mM glucose (pO.OOOl) and at 16.7 mM glucose (pO.OOOl).
- stimulation by forskolin increased insulin release approximately 9-fold at 3.3mM glucose (p ⁇ 0.0001) and approximately 18-fold at 16.7 mM glucose (pO.OOOl).
- the observed effects of forskolin on insulin release are in accord with previously published results.
- diabetic islets show a significantly smaller increase in insulin release as glucose concentration increases.
- control rats and diabetic rats release similar amounts of insulin at either high or low glucose levels.
- Example 2 Increased cAMP Levels in Islet Cells From Diabetic Animals cAMP levels were measured at low and high concentrations of glucose and in the presence and absence of forskolin to determine whether the results observed in Example 1 were due to increased sensitivity of diabetic islets to cAMP or to increased levels of cAMP in diabetic islets.
- Cyclic AMP was determined from the same batches of 20 islets in which insulin secretion was measured in Example 1. After removal of 900 ⁇ l for determination of insulin, the medium was replaced with 300 ⁇ l ice-cold acetate 9/41411
- Forskolin is known to strongly stimulate adenylate cyclase (AC) which catalyzes the conversion of ATP to cAMP. Forskolin stimulation fully restored the impaired insulin response to glucose in isolated diabetic islets. Moreover, forskolin markedly enhanced insulin responses at substimulatory glucose level in diabetic but not control islets.
- AC adenylate cyclase
- Example 3 Increased Expression of Adenylate Cyclase IH mRNA in Islet Cells From Diabetic Animals
- adenylate cyclase III mRNA were measured to determine whether increased levels cAMP generation in diabetic islets were due to increased amounts of the mRNA, and hence increased AC-HI protein, or, perhaps, the presence of a more active AC-III.
- Islets were isolated from both control and diabetic rats by digestion with collagenase (Boehringer-Mannheim). The islets were cultured for 48 hours in RPMI-1640 supplemented with 11 mM glucose and 10% (vol/vol) fetal calf serum. The islets were first pre-incubated in Krebs-Ringer bicarbonate (KRB) buffer supplemented with 2g/l bovine plasma albumin (Sigma) with 3.3 mM glucose for 45 minutes. Duplicate batches of 20 islets were subsequently incubated at 37 °C for 45 minutes in 1000 ⁇ l KRB supplemented with 3.3 mM or 16.7 mM glucose alone and with 5 ⁇ M forskolin (Sigma) at both glucose concentrations.
- KRB Krebs-Ringer bicarbonate
- Sigma bovine plasma albumin
- the labeling was performed with deoxyadenosine 5'- ⁇ -thiotriphosphate (i S) (New England Nuclear, USA) with terminal deoxynucleotidyl transferase (Amersham, UK).
- i S deoxyadenosine 5'- ⁇ -thiotriphosphate
- Amersham, UK terminal deoxynucleotidyl transferase
- a mixture of four different oligonucleotide probes each approximately 48 bases long and binding to different regions of rat AC-III mRNA were employed in order to increase the sensitivity of the method.
- the AC-HI mRNA sequence (Bakalyar and Reed, (1990).
- islet cells expressing mRNA for adenylate cyclase were examined in dark field microscopy and presented at X200 magnification. Control probes produced a uniformly weak background signal without revealing any positive cells.
- Example 4 Mutant Promoter in the Adenylate Cyclase HI Gene of Islet Cells From Diabetic Animals
- regulatory elements of the - adenylate cyclase III gene from these diabetic animals were examined for mutations.
- Mutations could influence tire rate or amount of adenylate cyclase gene transcription.
- Islets were isolated from six control and six GK rats by digestion with collagenase (Boehringer-Mannheim). The islets were cultured for 48 hours in RPMI-1640 supplemented with 11 mM glucose and 10% (vol/vol) fetal calf serum. Blood was collected from the same rats from which the islets were isolated. Islets and blood from every two GK and Wistar rats were pooled. Additionally, blood was also collected from another nondiabetic rat strain, the DA strain. DNA from leukocytes in peripheral blood was extracted by a modified
- PCR primers for amplifying the AC-III promoter region were designed using the computer program Oligo 5.0 (NBI, USA) using an adenylate cyclase gene sequence from GenBank account number S64908 (Wang, et al., Genes encoding components of the olfactory signal transduction cascade contain a DNA binding site that may direct neu onal expression. Mol. Cell. Biol. 13, 5805-5813, 1993).
- a forward primer corresponding to positions -563 to -549 relative to the transcription on start site was linked with an 18-bp-21 Ml 3 sequence resulting in primer sequence TGTAAAACGACGGCCAGTTCTTGAGCTGCCTCCCAAAG (SEQ. ID. NO. 8).
- the reverse primer corresponded to positions +263 to +282 relative to the transcription start site and had the sequence GTTCAGCATCCGTGGTCGCA (SEQ. ID. NO. 9).
- the PCR reaction volume 100 ⁇ l contained 200 nM dNTP, 1.5 ⁇ M MgCK 5 U Taq. polymerase (Pharmacia, Sweden), 0.2 ⁇ M primers and 1 ⁇ g DNA.
- PCR was carried out in Gene-AMP 9600 cycler (Perkin-Elmer, USA) for 35 cycles of 96 °C for 10 s, 60 °C for one minute and 72 °C for one minute. Purity of PCR products was evaluated on a 1% agarose gel and subsequently purified with A icon- 100 column (Amicon).
- the promoter region of the AC-III gene of control and diabetic animals was screened for mutations by sequencing.
- a genomic DNA fragment of the AC-III gene of 825 bp was sequenced, which included 563 bp in the 5' untranslated region.
- a luciferase reporter vector pGL3 -enhancer vector (Promega, USA), which allows for a foreign promoter to be inserted and results in luciferase gene expression in transfected host cells, was used to compare the activity of the AC-IH gene promoter of diabetic and control rats.
- the 5' end of the two primers had SAC I and Hind III sites, respectively, to facilitate cloning (the 5' primer TTTTGAGCTCTCTTGAGCTGCCTCCCAAAG (SEQ. ID. NO.
- the PCR reactions and cycle conditions are described in Example 4.
- the PCR products were cloned by double digestion with Sac I and Hind HI (Boehringer) using 20 units of restriction enzymes per 1 ⁇ g DNA and ligation to similarly cut vector DNA.
- the cloned inserts were confirmed by DNA sequencing using a dye terminator cycle sequencing kit with Ampli Taq. FA (Perkin-Elmer) and RV primer 3.
- the correct sequence containing the two novel mutations from GK rats or a corresponding fragment from control rats (wild -type) were inserted in a pGL3 -enhancer vector.
- the COS cells used for transfection were cultured in Dulbecco's medium containing sodium pyruvate, 1 g/1 glucose, 10% fetal bovine serum and 10 ⁇ l/mL gentamycin.
- the transfection of the recombi ⁇ ant vectors into COS cells was performed by Transfectam Reagent (Promega), according to the kit protocol. In this experiment, a mixture of 5 ⁇ g DNA with lO ⁇ l Transfectam was added to 5 X 10 5 COS cells prepared one day before.
- the pGL3 -control vector and pGLE-enhancer vector without any inserts were also transfected simultaneously as positive and negative controls of transfection, respectively. Each DNA was transfected into at least five dishes of COS cells as five parallel experiments.
- the luciferase activity produced in COS cells was detected by a scintillation counter (LS 6000SC, Beckman) after 48-hour cell culture, according to instructions of the luciferase assay system (Promega). One-minute counting time was selected to determine light intensity in individual samples and initiate each sample reaction immediately before measurement. Light intensity (proportional to luciferase activity) is expressed as the sum of the square root of measured counts per minute (cpm) minus background cpm.
- the luciferase activity from the pGL3-control vector used for monitoring the transfection efficiency was the highest among all the observations with a light intensity of 2257 + 299 light intensity units which indicated successful transfection in our reporter system. In contrast, results of negative transfection control with ⁇ GL3 -enhancer vector alone was 6 + 1 similar to background level 5 + 1 light intensity units (COS cells without vectors).
- luciferase vectors carrying the mutant or the normal AC-III promoter fragments were cotransfected with pCAT3-control vectors (Promega) as internal control plasmid for normalization of transfection efficiency.
- pCAT3-control vectors Promega
- 2 ⁇ g luciferase vector and 2 ⁇ g pCAT3 -control vector mixed with 8 ⁇ l Transfectam were cotransfected in each cell preparation (2.5 x 10 COS cells in 6-well plates), Cotransfections were performed in at least three cell preparations. Groups of cotransfected cells were incubated for 48 h without and with 5 ⁇ M forskolin. After 48 h, the cells were harvested using 200 ⁇ l reported lysis buffer (Promega) and divided into two parts for estimation of luciferase and CAT activities.
- CAT activity was determined as described above.
- CAT assay was performed using C-labe]ed chloramphenicol (DuPont, USA) and n-butyryl coenzyme A, following the CAT assay kit description (Promega).
- COS cells were transfected with pCAT-3 control vectors together with vectors carrying either the enhanced AC-i ⁇ promoter from diabetic animals or the wild-type AC-HI promoter. The results are presented in
- FIG. 5 An approximately 24-fold increase in luciferase activity was obtained from vectors carrying the enhanced promoter from diabetic animals (3660 ⁇ 250 light intensity units) compared to vectors carrying the wild-type AC-III promoter (153 ⁇ 57 light intensity units, p ⁇ 0.0002). Addition of forskolin did not amplify these responses. In the presence of forskolin, the enhanced promoter from diabetic animals produced 2441 ⁇ 253 light intensity units and vectors carrying the wild-type AC-HI promoter produced 95 ⁇ 31 light intensity units, pO,0008. These results suggest that the effects of forskolin on AC-III message levels is mediated by a post- transcriptional mechanism.
- the AC-III gene from diabetic rats has a promoter with activity that is enhanced compared to the wild type promoter.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000531591A JP2002503483A (en) | 1998-02-11 | 1999-02-11 | Methods of diagnosing and treating glucose metabolism disorders |
AU26512/99A AU2651299A (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
EP99906659A EP1053356A2 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
CA002319065A CA2319065A1 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7442798P | 1998-02-11 | 1998-02-11 | |
US60/074,427 | 1998-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999041411A2 true WO1999041411A2 (en) | 1999-08-19 |
WO1999041411A3 WO1999041411A3 (en) | 1999-09-30 |
Family
ID=22119512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1999/000177 WO1999041411A2 (en) | 1998-02-11 | 1999-02-11 | Method for diagnosis and treatment of disorders of carbohydrate metabolism |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1053356A2 (en) |
JP (1) | JP2002503483A (en) |
AU (1) | AU2651299A (en) |
CA (1) | CA2319065A1 (en) |
WO (1) | WO1999041411A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014427A2 (en) * | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
WO1996036641A1 (en) * | 1995-05-19 | 1996-11-21 | The Johns Hopkins University School Of Medicine | Susceptibility gene for obesity and type ii diabetes mellitus |
WO1997004331A1 (en) * | 1995-07-20 | 1997-02-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance |
-
1999
- 1999-02-11 EP EP99906659A patent/EP1053356A2/en not_active Withdrawn
- 1999-02-11 AU AU26512/99A patent/AU2651299A/en not_active Abandoned
- 1999-02-11 CA CA002319065A patent/CA2319065A1/en not_active Abandoned
- 1999-02-11 JP JP2000531591A patent/JP2002503483A/en active Pending
- 1999-02-11 WO PCT/SE1999/000177 patent/WO1999041411A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014427A2 (en) * | 1992-12-23 | 1994-07-07 | Zymogenetics, Inc. | Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation |
WO1996036641A1 (en) * | 1995-05-19 | 1996-11-21 | The Johns Hopkins University School Of Medicine | Susceptibility gene for obesity and type ii diabetes mellitus |
WO1997004331A1 (en) * | 1995-07-20 | 1997-02-06 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | System and method for performing in vivo imaging and oxymetry and ft microscopy by pulsed radiofrequency electron paramagnetic resonance |
Non-Patent Citations (1)
Title |
---|
ABDEL-HALIM S ET AL: "Mutations in the promoter of adenyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in Islets from the spontaneously diabetic GK RAT Model of Type 2 Diabetes" DIABETES, vol. 47, no. 3, March 1998 (1998-03), pages 498-504, XP002110194 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999041411A3 (en) | 1999-09-30 |
AU2651299A (en) | 1999-08-30 |
EP1053356A2 (en) | 2000-11-22 |
JP2002503483A (en) | 2002-02-05 |
CA2319065A1 (en) | 1999-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lantz et al. | Foxa2 regulates multiple pathways of insulin secretion | |
Abdel-Halim et al. | Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. | |
Gerber et al. | Compound heterozygosity for severe and hypomorphic NDUFS2 mutations cause non-syndromic LHON-like optic neuropathy | |
US20070212723A1 (en) | Human sodium channel isoforms | |
EP1842920B2 (en) | Cells coexpressing vitamin K reductase and vitamin K dependent protein and use thereof to improve the productivity of said vitamin K dependent protein | |
WO2011031786A2 (en) | Compositions and methods for diagnosing autism spectrum disorders | |
Fulcher et al. | Identification of a unique μ‐class glutathione S‐transferase in mouse spermatogenic cells | |
Westin et al. | Telomere restoration and extension of proliferative lifespan in dyskeratosis congenita fibroblasts | |
JP5608863B2 (en) | Methods for detecting refractory epilepsy from neonatal to infancy | |
US20070218469A1 (en) | Novel mutations in hexosaminidase A | |
US7488576B2 (en) | Methods for diagnosis and treatment of psychiatric disorders | |
Wildin et al. | AVPR2 variants and V2 vasopressin receptor function in nephrogenic diabetes insipidus | |
US20140322711A1 (en) | Spinocerebellar ataxia type 8 and methods of detection | |
Sutomo et al. | Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome | |
Xiang et al. | Mice lacking three loci encoding 14 glutathione transferase genes: a novel tool for assigning function to the GSTP, GSTM, and GSTT families | |
Maxwell et al. | Novel PEX1 mutations and genotype–phenotype correlations in Australasian peroxisome biogenesis disorder patients | |
Skak et al. | The TATA-less rat GAD65 promoter can be activated by Sp1 through non-consensus elements | |
WO1999041411A2 (en) | Method for diagnosis and treatment of disorders of carbohydrate metabolism | |
AU2003255513B2 (en) | Use of PP2A phosphatase modulators in the treatment of mental disorders | |
Stathakis et al. | Genomic organization of human DLG4, the gene encoding postsynaptic density 95 | |
Becker et al. | Identification of two novel nonsense mutations in the transglutaminase 1 gene in a Hungarian patient with congenital ichthyosiform erythroderma | |
Burtey et al. | Mutation screening of the PKD1 transcript by RT-PCR | |
US20100166880A1 (en) | Method for treatment and diagnosis of glutamate dehydrogenase disorders | |
Li et al. | Molecular and genetic approaches to understanding alcohol-seeking behavior | |
JP2001252086A (en) | Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase in: |
Ref document number: 2319065 Country of ref document: CA Ref country code: CA Ref document number: 2319065 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999906659 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09600378 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999906659 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999906659 Country of ref document: EP |